Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Prostatic Neoplasms 53Neoplasm Metastasis 11Neoplasms 8Recurrence 7Prostate Cancer Metastatic 6Breast Neoplasms 5Carcinoma, Transitional Cell 4Stomach Neoplasms 3Neoplastic Cells, Circulating 3Metastatic Castration-resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Thrombocytosis 1Testicular Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Prostate Cancer, Hereditary, 7 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Myeloproliferative Disorders 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × cabazitaxel × Clear all
NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed
26 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01747239 2014-12-04

Cabazitaxel in Platinum Refractory Ovarian Cancer

Vejle Hospital

Phase 2 Terminated
4 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡